A 151892 | 293759-27-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: A 151892
• 英文别名: N-[2-(2,2,2-Trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide；N-[2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)naphthalen-1-yl]acetamide
• CAS: 293759-27-0
• 化学式: C₁₅H₁₁F₆NO₂
• 分子量: 351.248
• InChiKey: LZGACSIEPSVAQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  A 151892 在 溴 、 sodium acetate 作用下， 生成 N-[4-Bromo-2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]-acetamide
  参考文献：
  名称：

  Structure–activity relationship of a novel class of naphthyl amide KATP channel openers

  摘要：

  We have discovered a novel series of N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl] amides that are potent openers of K-ATP channels and investigated structure-activity relationships (SAR) around the 1,2-disubstituted naphthyl core. A-151892, a prototype compound of this series, was found to be a potent and efficacious potassium channel opener in vitro in transfected Kir6.2/SUR2B cells and pig bladder strips. Additionally, A-151892 was found to selectively inhibit unstable bladder contractions in vivo in an obstructed rat model of myogenic bladder function. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00205-1
• 作为产物：
  描述：

  ethyl acetate n-hexane 、 1-Amino-2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)naphthalene 在 乙酸酐 作用下， 以 正己烷 为溶剂， 以61%的产率得到A 151892
  参考文献：
  名称：

  Naphthalene amides as potassium channel openers

  摘要：

  本发明涉及化合物及其作为钾通道开放剂的能力。

  公开号：

  US20030199578A1

文献信息

• Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
  申请人：Herlands Louis

  公开号：US20070026079A1

  公开（公告）日：2007-02-01

  Provided are methods of increasing K ATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
• Modulation of Hypothalamic Atp-Sensitive Potassium Channels
  申请人：Rossetti Luciano

  公开号：US20090012067A1

  公开（公告）日：2009-01-08

  Provided are methods of increasing K ATP activity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.
• [EN] NAPHTHALENE AMIDES AS POTASSIUM CHANNEL OPENERS<br/>[FR] AMIDES DU NAPHTALENE UTILISES COMME AGENTS D'OUVERTURE DU CANAL POTASSIQUE
  申请人：ABBOTT LAB

  公开号：WO2003089404A1

  公开（公告）日：2003-10-30

  The present invention relates to naphthylamide compounds and their ability to act as potassium channel openers.